VAXIN CEO TO PRESENT AT FUTURE LEADERS IN THE BIOTECH INDUSTRY CONFERENCE
Gaithersburg, Maryland – March 17, 2015 – Vaxin, a clinical stage vaccine development company today announced that CEO Bill Enright will present at the Future Leaders in the Biotech Industry Conference this Friday in New York City. Now in its 22nd year, the annual event will be held at the Millennium Broadway Hotel & Conference Center.
Enright will speak at 1:50pm in room 506. His presentation is part of the Next Wave Track. In addition to providing a corporate overview, he will address Vaxin’s growth strategy following the company’s recent acquisition of Immune Targeting Systems, and related funding round.
About Vaxin Inc.
Vaxin Inc. is a clinical stage biotechnology company developing next-generation vaccines to address significant public health and biodefense needs. By leveraging the specific attributes of its two independent and complementary vaccine delivery platforms, Vaxin can rapidly design vaccines against a wide range of disease targets, including respiratory diseases, chronic infections and cancer. Vaxin’s NasoVAXTM platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. Our DensigenTM T-cell vaccine platform technology is uniquely suited to direct the immune response against traditionally difficult vaccine targets, including chronic infections and cancer, by directing an individual’s unique immune system against multiple target antigens rather than just one. Vaxin’s vaccines are easily manufactured, highly stable, and are designed to provide a safe, effective alternative to currently marketed products. www.vaxin.com.
Bill Enright, President & CEO
Source: Vaxin inc.